See more : Morguard Corporation (MRCBF) Income Statement Analysis – Financial Results
Complete financial analysis of Selecta Biosciences, Inc. (SELB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Selecta Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bumitama Agri Ltd. (2BU.F) Income Statement Analysis – Financial Results
- Lions Gate Entertainment Corp. (LGF-A) Income Statement Analysis – Financial Results
- Regional Health Properties, Inc. (RHE-PA) Income Statement Analysis – Financial Results
- Sugai Chemical Industry Co., Ltd. (4120.T) Income Statement Analysis – Financial Results
- PT Astra Otoparts Tbk (AUTO.JK) Income Statement Analysis – Financial Results
Selecta Biosciences, Inc. (SELB)
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 110.78M | 85.08M | 16.60M | 6.68M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Cost of Revenue | 0.00 | 72.38M | 68.74M | 54.51M | 42.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 38.40M | 16.34M | -37.91M | -36.07M | 903.00K | 207.00K | 8.08M | 6.01M | 3.04M |
| Gross Profit Ratio | 0.00% | 34.66% | 19.21% | -228.40% | -540.15% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 71.84M | 72.38M | 68.74M | 54.51M | 42.74M | 47.69M | 45.17M | 29.70M | 22.98M | 10.49M |
| General & Administrative | 40.58M | 23.86M | 20.94M | 18.91M | 16.39M | 18.24M | 18.83M | 13.05M | 8.34M | 7.95M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 40.58M | 23.86M | 20.94M | 18.91M | 16.39M | 18.24M | 18.83M | 13.05M | 8.34M | 7.95M |
| Other Expenses | 0.00 | 330.00K | 15.00K | 89.00K | -1.31M | 10.00K | -152.00K | 4.00K | -26.00K | -44.00K |
| Operating Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Cost & Expenses | 112.42M | 96.24M | 89.67M | 73.42M | 59.13M | 65.93M | 63.99M | 42.75M | 31.32M | 18.44M |
| Interest Income | 0.00 | 958.00K | 2.80M | 1.30M | 834.00K | 1.05M | 617.00K | 234.00K | 171.00K | 111.00K |
| Interest Expense | -2.83M | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M | 1.21M | 1.25M | 948.00K | 552.00K |
| Depreciation & Amortization | 764.00K | 1.62M | 15.00K | 89.00K | -1.31M | 975.00K | 750.00K | 802.00K | 1.04M | 864.00K |
| EBITDA | -86.42M | 16.16M | -4.58M | -56.73M | -53.76M | -65.01M | -63.94M | -34.67M | -24.29M | -14.58M |
| EBITDA Ratio | 0.00% | 14.58% | -5.39% | -341.82% | -805.17% | -7,199.56% | -30,886.96% | -428.88% | -404.03% | -479.57% |
| Operating Income | -86.42M | 14.54M | -4.60M | -56.82M | -52.46M | -65.02M | -63.78M | -34.67M | -25.30M | -15.40M |
| Operating Income Ratio | 0.00% | 13.12% | -5.40% | -342.36% | -785.61% | -7,200.66% | -30,813.53% | -428.92% | -420.96% | -506.55% |
| Total Other Income/Expenses | -152.29M | 20.23M | -5.12M | -12.06M | -2.90M | -314.00K | -1.54M | -1.54M | 130.00K | 2.52M |
| Income Before Tax | -238.71M | 34.77M | -9.72M | -68.88M | -55.35M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Income Before Tax Ratio | 0.00% | 31.39% | -11.43% | -414.99% | -828.97% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| Income Tax Expense | 19.00M | -609.00K | 15.97M | 911.00K | -1.81M | 1.18M | 304.00K | 455.00K | 922.00K | 508.00K |
| Net Income | -219.71M | 35.38M | -25.69M | -69.79M | -53.54M | -65.34M | -65.32M | -36.21M | -25.17M | -12.88M |
| Net Income Ratio | 0.00% | 31.94% | -30.19% | -420.48% | -801.80% | -7,235.44% | -31,556.04% | -447.98% | -418.80% | -423.68% |
| EPS | 0.00 | 0.24 | -0.22 | -0.69 | -1.18 | -2.92 | -3.20 | -3.45 | -1.96 | -1.00 |
| EPS Diluted | 0.00 | 0.10 | -0.22 | -0.69 | -1.18 | -2.92 | -3.20 | -3.45 | -1.96 | -1.00 |
| Weighted Avg Shares Out | 155.11B | 144.76M | 114.33M | 101.20M | 45.55M | 22.39M | 20.43M | 10.49M | 12.87M | 12.87M |
| Weighted Avg Shares Out (Dil) | 155.11B | 145.87M | 114.33M | 101.20M | 45.55M | 22.39M | 20.43M | 10.49M | 12.87M | 12.87M |
Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
Why Novartis, Seelos Therapeutics And More Are Moving Today
Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy
Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
Selecta: ImmTOR Platform's Potential In Key
Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call Transcript
Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
Source: https://incomestatements.info
Category: Stock Reports